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Background: Metastasized pancreatic neuroendocrine tumors are the leading cause of death in patients
with multiple endocrine neoplasia type 1. Aside from tumor size, prognostic factors of pancreatic
neuroendocrine tumors are largely unknown. The present study aimed to assess whether the prognosis
of patients with resected multiple endocrine neoplasia type 1-related nonfunctioning pancreatic
neuroendocrine tumors differs from those with resected multiple endocrine neoplasia type 1-related
insulinomas and assessed factors associated with prognosis.
Methods: Patients who underwent resection of a multiple endocrine neoplasia type 1-related pancreatic
neuroendocrine tumors between 1990 and 2016 were identified in 2 databases: the DutchMEN Study Group
and the International MEN1 Insulinoma Study Group databases. Cox regression was performed to compare
liver metastases-free survival of patients with a nonfunctioning pancreatic neuroendocrine tumors versus
those with an insulinoma and to identify factors associated with liver metastases-free survival.
Results: Out of 153 patients with multiple endocrine neoplasia type 1, 61 underwent resection for a
nonfunctioning pancreatic neuroendocrine tumor and 92 for an insulinoma. Of the patients with resected
lymph nodes, 56% (18/32) of nonfunctioning pancreatic neuroendocrine tumors had lymph node metas-
tases compared to 10% (4/41) of insulinomas (P ¼ .001). Estimated 10-year liver metastases-free survival
was 63% (95% confidence interval 42%e76%) for nonfunctioning pancreatic neuroendocrine tumors and
87% (72%e91%) for insulinomas. After adjustment for size, World Health Organization tumor grade, and
age, nonfunctioning pancreatic neuroendocrine tumors had an increased risk for liver metastases or death
(hazard ratio 3.04 [1.47e6.30]). In pancreatic neuroendocrine tumors 2 cm, nonfunctioning pancreatic
neuroendocrine tumors (2.99 [1.22e7.33]) and World Health Organization grade 2 (2.95 [1.02e8.50]) were
associated with liver metastases-free survival.
Conclusion: Patients with resected multiple endocrine neoplasia type 1-related nonfunctioning
pancreatic neuroendocrine tumors had a significantly lower liver metastases-free survival than patients
with insulinomas. Postoperative counseling and follow-up regimens should be tumor type specific and at
least consider size and World Health Organization grade.
© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Multiple endocrine neoplasia type 1 (MEN1) is an autosomal
dominant inherited cancer syndrome caused by a germline mutation
in the MEN1 tumor suppressor gene located on chromosome 11q13
encoding for the proteinmenin.1,2 The trait occurs in 2 to 3 per 100,000
persons.1 One of the hallmark manifestations of the disease isInc. This is an open access article upancreatic neuroendocrine tumors (pNETs), which have a prevalence
of 56%.3 Moreover, the age-related penetrance of pNETs gradually in-
creases to over 80% by the age of 80 years.3,4 Metastasized pNETs are
the leading cause of death in patients with MEN1 and significantly
reduce life expectancy.3,5,6
Clinically, pNETs are classified as nonfunctioning or functioning
tumors, depending on the presence of a distinct clinical syndromender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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atic neuroendocrine tumors (NF-pNETs) are the most prevalent
pNETs, whereas insulinomas are the most frequently encountered
functioning pNETs.7-10 Tumor formation occurs as a result of in-
dependent clonal events leading to a loss of heterozygosity of the
wild-type MEN1 allele, which is observed in pNETs, micro-
adenomas, and mono-hormonal endocrine cell clusters.11 Despite
the assumed shared origin of pNETs, varying survival rates have
been reported for patients with MEN1-related NF-pNETs and
functioning pNETs.5,12,13
Although the majority of pNETs in MEN1 follow a relatively
indolent natural course, a subgroup of pNETs metastasizes to the
liver and subsequently leads to decreased survival.6,12,14e16
Therapy should be aimed at maintaining a good quality of life
by relieving symptoms associated with excessive hormone
production as well as preventing liver metastases.17 Besides
tumor size as a predictor of liver metastases, prognostic factors
of MEN1-related pNETs are largely unknown. It is generally
assumed that insulinomas in MEN1 have a more favorable
prognosis compared with NF-pNETs because of a relatively small
tumor size, early symptomatology with subsequent treatment,
or because of differences in grade.5,8,18 Patient counseling is
inevitable in MEN1 daily clinical care considering the high, age-
related prevalence of pNETs, intensive lifelong screening pro-
grams, and considerable operative morbidity in those referred
for surgery.17,19 Nevertheless, the major unmet need for
adequate patient counseling is insight in prognosis of MEN1-
related pNETs.20,21 Knowledge of differences in prognostic fac-
tors will contribute to tailoring of surgical indications, timing
and extent of surgery, and postoperative follow-up regimens in
individual patients. Therefore, this study aimed to assess if pa-
tients with a resected MEN1-related NF-pNET have a different
prognosis than those with a resected MEN1-related insulinoma.
Furthermore, survival and factors associated with liver
metastases-free survival were assessed to come to meaningful
advice regarding postoperative counseling and follow-up spe-
cifically for NF-pNETs and insulinomas.
Methods
Study design and patient selection
For this observational study, patients with NF-pNETs and insu-
linomas were selected from the DutchMEN Study Group (DMSG)
cohort.22 Considering the rarity of MEN1-related insulinomas,
patients with a MEN1-related insulinoma were additionally iden-
tified from a MEN1 collaboration including European and North
American hospitals. Patients were eligible if they had a resection
for a NF-pNET or an insulinoma between 1990 and 2016 with
histopathological neuroendocrine tumor confirmation and were
followed for at least 1 year after surgery. MEN1 diagnosis was
established according to the most recent practice guidelines.17 Pa-
tients operated on for a pNET before 1990 or with distant metas-
tases at diagnosis were excluded. Patients with glucagonomas,
vasoactive intestinal peptidomas, and somatostatinomas were not
included considering their rarity (<2%).23 The study protocol was
approved by the medical ethics committees or institutional review
boards of all participating centers.
The DSMG database22
The DMSG database includes patients with MEN1 aged 16 years
and older under treatment in 1 of the Dutch University Medical
Centers. Patients were identified by review of the hospital diagnosis
databases. Over 90% of the total DutchMEN1 population is includedin the database. Clinical and demographic datawere collected every
3 months by standardized medical record review, according to a
predefined protocol.
International MEN1 Insulinoma Study Group24
The collaboration includes the population-based database
from the DMSG, the national database from the Groupe d’etude
des Tumeurs Endocrines (GTE) from France, and 7 MEN1 expert
centers including European and North American hospitals. Pa-
tients with a MEN1-related insulinoma were identified by re-
view of the hospital databases using International Classification
of Diseases codes.24 Clinical and demographic data were gath-
ered by investigators from every hospital according to the same
predefined protocol.
Clinical definitions
A pNET was considered as NF-pNET in case of positive histo-
pathology or computed tomography (CT), magnetic resonance
imaging (MRI), and/or endoscopic ultrasonography diagnostic of a
pNET in combination with the absence of excessive hormone pro-
duction provoking a distinct clinical tumor syndrome.16 The date of
diagnosis was recorded as the date of the first positive imaging or
the date of pathology.16,25
The presence of an insulinoma was based on a positive, 48- to
72-hour supervised fast test.26,27 If no 72-hour supervised fast
test was performed, the insulinoma diagnosis was based on
clinical criteria: symptoms or signs of hypoglycemia with
concomitant biochemical endogenous hyperinsulinemic hypo-
glycemia according to clinical practice guidelines.26,27 The date
of diagnosis was based on the date of the supervised fast test or
the date of symptoms accompanied by endogenous hyper-
insulinemic hypoglycemia. Patients with an insulinoma were
analyzed in the insulinoma group, also in the presence of
coexisting NF-pNETs.
Gastrinomas in MEN1 have a predominant duodenal origin and
rarely occur in the pancreas.10,28,29 Therefore, patients with
hypergastrinemia and a pNET were regarded as patients with a co-
existing duodenal gastrinoma.
Multiple enucleations, a distal pancreatectomy plus enucleation,
Whipple plus enucleation, andWhipple plus distal pancreatectomy
were considered as combined resections.
Pathology
Pancreatic specimens were examined for the number of
pNETs and size of the largest pNET. The size of the largest pNET
was used for analysis. In patients with a resection for an insu-
linoma, positive immunohistochemistry for insulin classified the
tumor as insulinoma. If insulin staining was negative or if
detailed information on immunohistochemical staining was
missing, the size of the largest pNET was used for analysis.
Specimens were examined for lymph node metastases. Any
peripancreatic lymph node harboring neuroendocrine tumor
cells was considered as lymph node metastasis, regardless of
hormone expression. If no lymph nodes were observed during
the examination, itwas assumed that no lymph nodeswere resected.
Tumors were examined for mitotic rate and Ki67 labeling. Tumor
grade was classified according to the World Health Organization
(WHO) 2017 classification: Grade 1 (G1): Ki67 labelling index (LI) <3
andmitosis<2 per 10 high power fields (HPF); G2: Ki67 LI 3e20 and/
or mitoses 2e20/10 HPF; G3 Ki67 LI >20 and/or mitosis >20/10
HPF.30 In case of a contradiction between mitotic rate and Ki67 la-
beling, WHO grade was determined by the highest of both.31,32
Fig 1. Flowchart of patient inclusion. GHRH, growth hormone-releasing hormone.
Table I
Demographic, preoperative, surgical, and histopathological characteristics
Characteristic Overall (n ¼ 153) NF-pNET (n ¼ 61) Insulinoma (n ¼ 92) P value
Age at pNET diagnosis in y, median [range] 36 [6e82] 40 [15e73] 32 [6e82] .002
Missing data (%) 1 (1%) 0 (0%) 1 (1%)
Age at surgery in y, median [range] 38 [6e82] 41 [20e73] 34 [6e82] .002
Time from diagnosis until surgery in y, median [range] 0.5 [0e15] 0.5 [0e15] 0.3 [0e15] .006
Missing data (%) 1 (1%) 0 1 (1%)
Sex (%)
Male 66 (43%) 34 (56%) 32 (35%) .010
Female 87 (57%) 27 (44%) 60 (65%)
Size largest pNET on preoperative imaging in mm, median [range] 20 [4e98] 27 [8e86] 20 [4e98] .009
Missing data (%) 18 (12%) 5 (8%) 13 (14%)
Number of pNETs on preoperative imaging (%)
0 5 (3%) 4 (7%) 1 (1%) .221
1 71 (46%) 29 (48%) 42 (48%)
2 29 (19%) 9 (15%) 20 (23%)
3 42 (28%) 18 (30%) 24 (28%)
Missing data (%) 6 (4%) 1 (1%) 5 (5%)
Suspected lymph node metastases on preoperative conventional imaging (%) 5 (3%) 5 (8%) 0 (0%) .009
Missing data (%) 1 (1%) 0 1 (1%)
Type of resection (%)
Enucleation 23 (15%) 9 (15%) 14 (15%) -
Multiple enucleations 6 (4%) 2 (3%) 4 (4%)
Distal pancreatectomy 71 (46%) 33 (54%) 38 (41%)
Distal pancreatectomy and enucleation 27 (18%) 2 (3%) 25 (27%)
Whipple or PPPD 10 (7%) 5 (8%) 5 (5%)
Whipple/PPPD and enucleation 2 (1%) 0 (0%) 2 (2%)
Whipple/PPPD and distal pancreatectomy 5 (3%) 3 (5%) 2 (2%)
Pancreatic body resection 1 (1%) 1 (2%) 0 (0%)
Total pancreatectomy 8 (5%) 6 (10%) 2 (2%)
Combined resection (%) 40 (26.1%) 7 (12%) 33 (36%) .001
Number of pNETs in the resection specimen (%)
1 39 (26%) 18 (30%) 21 (24%) .100
2 27 (18%) 15 (25%) 12 (14%)
3 83 (56%) 28 (46%) 55 (63%)
Missing data (%) 3 (2%) 0 (0%) 4 (4%)
Size largest pNET pathology in mm, median [range] 20 [3e120] 25 [3e120] 20 [5e110] .045
Missing data (%) 13 (8%) 3 (5%) 10 (11%)
Lymph node metastases (%)
Lymph node metastases 22 (14%) 18 (30%) 4 (4%) < .001
No lymph node metastases 51 (33%) 14 (23%) 37 (40%)
No lymph nodes resected 61 (40%) 29 (48%) 32 (35%)
Missing data (%) 19 (12%) 0 (0%) 19 (21%)
WHO grade
G1 87 (78%) 45 (79%) 42 (76%) .539
G2 24 (21%) 11 (19%) 13 (24%)
G3 1 (1%) 1 (2%) 0
Missing data (%) 41 (27%) 4 (7%) 37 (40%)
PPPD, pylorus-preserving pancreatoduodenectomy.
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Fig 2. (A) LMFS of patients with resected MEN1-related pancreatic neuroendocrine
tumors. (B) LMFS of patients with resected MEN1-related pancreatic neuroendocrine
tumors <2 cm. (C) LMFS of patients with resected MEN1-related pancreatic neuro-
endocrine tumors 2 cm.
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tumor characteristics from the first resection were used for anal-
ysis. If the time between 2 resections was less than 3 months,
characteristics of the largest tumor were obtained, since it is to be
expected that the largest tumor was present at the time of the first
operation and likely determines prognosis.
Outcomes
Primary outcomes were the occurrence of pNET-related liver
metastases during follow-up and overall survival. A composite
endpoint (pNET liver metastases and/or overall survival) was
computed. Liver metastases were defined as (1) pathologically
proven or (2) radiologically confirmed. If at least 2 consecutive CT/
MRI reports described lesions suspicious for liver metastases,
radiology was documented as positive. Pre- and postoperative
assessment of the liver was performed according to local avail-
ability of imaging modalities and considered conventional imaging
(CT or MRI) during the study period. Intraoperative assessment of
the liver was guided by the individual surgeon’s preference and
might have included bimanual palpation or intraoperative ultraso-
nography. The most likely cause of liver metastases was determined
by multidisciplinary team discussion. Causes of death were captured
from medical records. Deaths caused by MEN1 manifestations and
MEN1-related therapy were considered as MEN1-related. Other
causes of death were regarded as non-MEN1-related.3
Statistical analysis
Continuous variables were reported as median (range or inter-
quartile range [IQR]) and categorical variables as counts (pro-
portions). Mann-Whitney U tests were used for comparison of
continuous variables, and categorical variables were compared
using c2 or Fisher exact tests. Follow-up time started at the date of
surgery and ended at the date of (1) diagnosis of pNET-related liver
metastases or (2) death or (3) last follow-up (ie, date of last visit or
Jan 1st 2018). Kaplan-Meier curves were plotted and survival
probability estimates were obtained.33 The log-rank test was used
for univariable survival comparison. Pancreatic neuroendocrine
tumor size was dichotomized to <2 cm and 2 cm.25,34
Univariable and multivariable Cox proportional hazard
regression analyses were performed with the time to pNET-
related liver metastases or death as outcome. Considering the
relatively low number of outcomes, 4 covariates could be
included in the multivariable analysis, which were selected
based on clinical reasoning and previous literature.4,25,31 Be-
sides pNET functionality (NF-pNET versus insulinoma), pNET
size in mm, WHO grade (G2/G3 versus G1), and age in years
were included in the model.4,25,31 A stratified Cox model was
performed for pNETs <2 cm and 2 cm. Crude and adjusted
hazard ratios (HR) and corresponding 95% confidence intervals
(95% CI) were calculated. Cox proportional hazard regression
assumptions were formally tested and graphically assessed
using scaled Schoenfeld residuals; the assumptions were not
violated. Tied events were handled using the exact method. A
sensitivity analysis was performed including pNET function-
ality (NF-pNET versus insulinoma), pNET size in mm, and
lymph node status (metastases versus none resected versus no
metastases).
In addition, univariable Kaplan-Meier and/or Cox propor-
tional hazard regression were performed to assess the influence
of age at surgery (in years), sex (female versus male), pNET size
in mm, pNET size (2 cm vs <2 cm), pNET functionality (NF-
pNET versus insulinoma), WHO grade (G2/G3 versus G1), lymph
node status (lymph node metastases versus no lymph nodemetastases versus no lymph nodes resected), and time from
diagnosis until surgery (in years) on time to liver metastases or
death. The latter analyses were additionally performed for the
subgroups of NF-pNETs and insulinomas. In addition, these an-
alyses were performed with pNET size arbitrarily categorized
into <2 cm, 2 to 3 cm, and 3 cm.
Missing data were encountered for variables used in the Cox
regression, and these were considered as missing at random and,
therefore, imputed using multiple imputation with the iterative
Markov chain Monte Carlo method creating 40 datasets.35,36
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Fig 3. (A) Occurrence of liver metastases or death stratified by pNET size and pNET functionality in total cohort. (B) Occurrence of liver metastases or death stratified by pNET size
for patients with a resected NF-pNET. (C) Occurrence of liver metastases or death stratified by pNET size for patients with a resected insulinoma.
Table II
Multivariable analysis for factors associated with liver
metastases or death
Characteristic Multivariable
analysis (adjusted
HR)
HR 95% CI
Age at surgery (per y) 1.02 0.99e1.05
Size largest pNET (per mm) 1.01 1.001e1.02
Tumor functionality
Insulinoma 1 Ref cat
NF-pNET 3.04 1.47e6.30
WHO grade
G1 1 Ref cat
G2/G3 2.09 0.89e4.90
Data reported after multiple imputation.
Multivariable analysis included all factors listed above.
cat, category; Ref, reference.
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multiple imputation, together with the primary outcome (known
in all patients) and the Nelson-Aalen estimator.37,38 For multiple
imputation of time-to-event data, the event and the censoring time
should be taken into account. The cumulative baseline hazard at the
time of the event or censoring is often unknown but can be
approximated by the Nelson-Aalen estimator.38 HRs with corre-
sponding 95% CIs were pooled using Rubin’s rules.39
P values of < .05 were considered statistically significant. Sta-
tistical analysis was performed using SPSS version 25.0 (IBM Corp,
Armonk, NY), R version 3.4.1 (R Foundation for Statistical
Computing, Vienna, Austria) with ‘survival’ and ‘Mice’ packages,
and Graphpad Prism version 7.02 (GraphPad Software, Inc, San
Diego, CA).
Results
A total of 153 patients underwent resection for a pNET, 61 for
a NF-pNET and 92 for an insulinoma (Fig 1). Baseline charac-
teristics are shown in Table I. Patients with NF-pNETs were older
at diagnosis, older at surgery, more often male, had larger tu-
mors on imaging, more often with suspected lymph node me-
tastases on imaging, and a longer time between diagnosis and
surgery. Twenty-six patients (41%) in the NF-pNET group and 15
patients (16%) in the insulinoma group were operated on more
than 1 year after diagnosis. Combined resections were more
often performed for insulinomas. All insulinoma patients, except
1, were cured from hyperinsulinemic hypoglycemia immediately
postoperative.
Pathology
Median size of the largest pNET in the surgical specimen was
larger for NF-pNETs compared with insulinomas (median 25 mm
[IQR 15e35 mm] vs 20 mm [IQR 15e25 mm], respectively;
Table I). Tumor size, lymph node status, and WHO grade were
missing in 8%, 12%, and 27%, respectively. Thirty-eight NF-pNETs
(64%; 38/59) and 47 insulinomas (57%; 47/82) were larger than 2
cm. Multiple insulin immunopositive pNETs were observed in 24
(30%) patients with insulinomas. Three patients in the insuli-
noma group had negative insulin immunohistochemistry, all of
whom were cured.
Of the 73 patients with lymph nodes resected, lymph nodes
were tumor positive in 18 patients with NF-pNETs (56%; 18/32)
compared to 4 (10%; 4/41) with insulinomas (P < 0.001; Table I).
Lymph node metastases were more often observed in patients with
a pNET 2 cm (17/44, 39%) compared with pNET <2 cm (4/25, 16%)
(P ¼ .050); 3 patients with lymph node metastases had missingtumor size. Of the 44 patients with resected lymph nodes and a
pNET 2 cm, metastatic lymph nodes were observed in 15 patients
(63%; 15/24) with NF-pNETs compared with 2 patients (10%; 2/20)
with insulinomas (P ¼ .001). No differences in WHO grade (Ki-67
and/or mitosis) were observed between NF-pNETs and insulino-
mas. In 1 patient, the NF-pNETwas considered awell-differentiated
WHO G3 tumor.
Long-term outcomes
Long-term outcomes are summarized in Supplementary
Table I. After a median follow-up of 8.8 years (range
0.3e25.3 years), 37 patients (24%) had developed liver me-
tastases or died, which occurred more often in patients with
NF-pNETs compared to insulinomas (22/61 (36%) vs 15/92
(16%); P ¼ .005). No differences were observed regarding
follow-up time between the NF-pNETs and insulinoma group.
Liver metastases were observed in 15 patients (25%) with a NF-
pNET and 6 (7%) with an insulinoma. Two of the 6 patients
with a resected insulinoma had recurrent hypoglycemia at the
time of liver metastases diagnosis. Median time from surgery
until the development of liver metastases or death was
significantly shorter for NF-pNETs (5.3 vs 9.5 years; P ¼ .036).
The development of subsequent liver metastases or death
occurred after 5 and 10 years in 24 (65%) and 11 patients (30%),
respectively. Causes of death are listed in Supplementary
Table II. The percentage of liver metastases, death, or both
correlated with tumor size (Fig 2). The proportion of patients
with NF-pNETs developing liver metastases was higher for all
D.-J. van Beek et al. / Surgery xxx (2020) 1e116tumor sizes (<2, 2e3, and 3 cm) compared to patients with
an insulinoma, whereas patients with a resected insulinoma
tended to die more often without pNET-related liver
metastases.Liver metastases-free survival after resection of NF-pNETs versus
insulinomas
Patients with a resected NF-pNET had a significantly reduced
liver metastases-free survival (LMFS) compared to those with a
resected insulinoma (log-rank P value .002) (Fig 3). Ten-year LMFS
probability estimates were 63% (95% CI 42%e76%) for NF-pNETs vs
87% (95% CI 72%e91%) for insulinomas. Of the 60 patients with
pNETs <2 cm, 9 (15%) developed liver metastases or died; no sur-
vival differences were observed between patients with NF-pNETs
and insulinomas (Fig 3, B). In contrast, 28 of the 93 patients (30%)
with a pNET 2 cm developed liver metastases or died, and LMFS
was significantly lower for patients with NF-pNETs 2 cm
compared to insulinomas 2 cm (P ¼ .011; Fig 3, C).
After adjusting for age at surgery, pNET size, and WHO
grade, patients with a resected NF-pNET had a significantly
increased risk for liver metastases or death compared to pa-
tients with a resected insulinoma (HR 3.04 [95% CI 1.47e6.30];
Table II). In addition, pNET size per mm increase (HR 1.01 [95%
CI 1.001e1.02]) was independent of pNET type, WHO grade,
and age at surgery associated with LMFS. Sensitivity analysis
showed similar HRs for pNET functionality and size when
adjusted for lymph node status (Supplementary Table III).
Stratified by pNET size <2 and2 cm, no factors were associated
with LMFS in pNETs <2 cm (Table III). For pNETs 2 cm, NF-pNETs
were associated with LMFS after adjusting for age at surgery and
WHO grade (HR 2.95 [95% CI 1.18e6.67]). In addition, patients with
WHO G2 tumors had an increased risk for liver metastases or death
(HR 2.52 [95% CI 1.16e5.47]).
Prognostic factors for LMFS
Estimated LMFS probabilities and factors associated with LMFS
are summarized in Table IV. Patients whowere older at surgery, had
a NF-pNETs versus an insulinoma, had larger pNETs, a pNET 2 cm
vs <2 cm, a WHO G2/G3 versus G1 tumor, lymph node metastases
versus no lymph node metastases, and a longer delay from diag-
nosis until surgery had higher probabilities of liver metastases orTable III
Univariable andmultivariable analysis for factors associated wi
cm
Characteristic No of patients LM
pNET
<2 cm
Age at surgery (per y) 60 9
Tumor functionality
Insulinoma 38 3
NF-pNET 22 6
pNET
2 cm
Age at surgery (per y) 93 28
Tumor functionality
Insulinoma 54 12
NF-pNET 39 16
WHO grade
G1 64 15
G2/G3 29 13
Data reported after multiple imputation.
Multivariable analysis includes age and tumor functionality; f
cat, category; Ref, reference.death. Ten-year LMFS probability estimates weremore than 80% for
patients with an insulinoma (87%), pNET <2 cm (87%), G1 tumor
(80%), and no lymph node metastases (81%). By contrast, for pa-
tients with a NF-pNET (63%), pNET 2 cm (42%) and G2/G3 tumor
(42%), and lymph node metastases (51%), LMFS probability esti-
mates were lower. Additional analysis revealed that patients with a
resected pNET 3 cm as compared to those with a resected pNET
<2 cm had a significantly decreased LMFS (HR 4.80 [95% CI
2.09e11.02]; Fig 4, Table V). No differences were observed for those
with a pNET 2 to 3 cm compared to those with a pNET <2 cm.
Estimated 5- and 10-year LMFS probabilities were 92% and 80% for
patients operated on before 2003 and 90% and 75% for patients
operated on from 2003 onwards.
Prognostic factors for LMFS in NF-pNETs
Within the patients with a resected NF-pNET, 10-year LMFS
probability estimates were 50% for those with a NF-pNET 2 cm,
24% for those with a WHO G2/G3 tumor, and 44% for those with
lymph node metastases. Size in mm (HR 1.02 [95% CI 1.01e1.04])
and WHO G2/G3 versus G1 (HR 2.99 [95% CI 1.19e7.54]) were
associated with LMFS. Of the patients with a NF-pNET 2 cm
graded as G2/G3, estimated 10-year LMFS was 23% compared with
84% for patients with a G1 NF-pNET <2 cm (Fig 5).
Prognostic factors for LMFS in insulinomas
A longer time from diagnosis until surgery was associated with
liver metastases or death in patients with a resected insulinoma.
The CIs of other factors, such as age at surgery, size in mm, presence
of a pNET 2 cm, and WHO G2/G3, crossed unity. Point estimates
and 95% CI of these factors had similar direction and magnitude as
within the NF-pNET group. Of the patients with complete data,
those with an insulinoma 2 cm, which was G2/G3, had an esti-
mated 10-year LMFS of 57%.
Discussion
This study shows that patients with a resected MEN1-related
NF-pNET had a reduced LMFS compared to those with a resected
MEN1-related insulinoma, irrespective of the age of surgery and the
size and WHO grade of the tumor. These observations suggest
differences in underlying tumor origin, development, or biology ofth liver metastases or death stratified for pNETs <2 and2
/death Univariable analysis
(crude HR)
Multivariable
analysis (adjusted
HR)
HR 95% CI HR 95% CI
1.03 0.98e1.08 1.03 0.98e1.08
1 Ref cat 1 Ref cat
2.44 0.58e10.30 2.19 0.52e9.28
1.02 0.99e1.06 1.01 0.98e1.05
1 Ref cat 1 Ref cat
3.11 1.39e6.98 2.92 1.28e6.67
1 Ref cat 1 Ref cat
2.13 0.998e4.55 2.52 1.16e5.47
or pNETs 2 cm, WHO grade was additionally included.
Table IV
LMFS and factors associated with LMFS
Subgroup Characteristic LMFS* Univariable Cox regressiony
5-y (%) 10-y (%) Log rank P value LM/death Crude HR 95% CI
Overall Age at surgery (per y) - - NA 37 of 153 1.03 1.01e1.06
Sex 87 77 .491 18 of 66 1 Ref cat
Male
Female 94 77 19 of 87 0.80 0.42e1.52
pNET functionality
Insulinoma 98 87 .002 15 of 92 1 Ref cat
NF-pNET 81 63 22 of 61 2.72 1.41e5.28
Size continuous (per mm) - - NA 37 of 153 1.02 1.01e1.03
pNET 2 cm
<2 cm 95 87 .003 9 of 60 1 Ref cat
2 cm 88 70 28 of 93 2.97 1.36e6.48
WHO grade
G1 93 80 .002 21 of 109 1 Ref cat
G2/G3 83 42 16 of 44 2.20 1.02e4.76
Lymph node status
No metastases 91 81 .144 12 of 60 1 Ref cat
None resected 90 76 16 of 69 1.35 0.61e2.99
Metastases 86 51 9 of 24 2.77 1.12e6.85
Y from diagnosis until surgery - - NA 37 of 153 1.12 1.01e1.24
NF-pNET Age at surgery (per y) - - NA 22 of 61 1.04 0.995e1.08
Sex
Male 80 68 .752 12 of 34 1 Ref cat
Female 84 58 10 of 27 1.15 0.85e1.51
Size continuous (per mm) - - NA 22 of 61 1.02 1.01e1.04
pNET 2 cm
<2 cm 86 86 .058 6 of 22 1 Ref cat
2 cm 80 50 16 of 39 2.37 0.89e6.34
WHO grade
G1 86 73 .046 14 of 47 1 Ref cat
G2/G3 74 24 8 of 14 2.99 1.19e7.54
Lymph node status
No metastases 77 77 .360 5 of 14 1 Ref cat
None resected 83 70 8 of 29 0.63 0.21e1.96
Metastases 82 44 9 of 18 1.28 0.42e3.94
Y from diagnosis until surgery - - NA 22 of 61 1.01 0.88e1.16
Insulinoma Age at surgery (per y) - - NA 15 of 92 1.02 0.99e1.06
Sex
Male 97 90 .784 6 of 32 1 Ref cat
Female 98 85 9 of 60 0.83 0.60e1.18
Size continuous (per mm) - - NA 15 of 92 1.01 0.998e1.03
pNET 2 cm
<2 cm 100 86 .068 3 of 40 1 Ref cat
2 cm 95 87 12 of 52 3.43 0.98e12.01
WHO grade
G1 100 90 .003 7 of 62 1 Ref cat
G2/G3 91 68 8 of 30 2.60 0.92e7.29
Lymph node status 97 83 .385 7 of 46 1 Ref cat
No metastases
None resected 97 82 8 of 40 1.91 0.66e5.54
Metastases 100 - 0 of 6 NA NA
Y from diagnosis until surgery - - NA 15 of 92 1.25 1.05e1.49
cat, category; NA, not applicable; Ref, reference.
* Estimated survival percentages are based on the patients with complete data.
y Data presented after multiple imputation.
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patients during follow-up should, therefore, be tumor-type specific
and at least include tumor size and WHO grade.
Previous studies hypothesized that patients with MEN1-related
insulinomas have favorable prognosis because of small tumor size,
early symptomatology with subsequent treatment, or because of
differences in grade.5,8,19 Indeed, in this study, patients with insu-
linomas were younger, had a shorter time from diagnosis to sur-
gery, and had smaller pNETs than patients with NF-pNETs. No
differences in WHO grade were observed between NF-pNETs and
insulinomas. Nevertheless, when adjusted for age at surgery, size,
andWHO grade, the risk of liver metastases or death was tripled for
patients with a resected NF-pNET compared to those with aresected insulinoma. This indicates that the pathology of NF-pNETs
likely is more aggressive.
Tumor size and WHO grade were associated with LMFS, also
after adjusting for pNET type and age. Although size has been
extensively studied and translated in clinical decision making, the
present study observed that sizeeon a continuous scaleewas
associated with long-term outcomes and might therefore be used
for postoperative counseling.12,25,34,40 In line with tumor size on a
continuous scale being associated with LMFS, subsequent analyses
revealed that especially patients with a resected pNET of at least 3
cm had the highest chance of subsequent liver metastases or death,
regardless of pNET functionality. Although a randomized controlled
trial is ideally demanded to determine whether surgery has added
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2 - 3 cm 46 42 31 24 19 15 9 6
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Fig 4. LMFS of patients with resected MEN1-related pancreatic neuroendocrine tu-
mors stratified by tumor size (<2 cm, 2e3 cm, and 3 cm).
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might hypothesize that a MEN1-related pNET should ideally be
resected before the 3cm cutoff is reached. These observations
further underscore the importance of accurate size estima-
tions.41 It has previously been observed within the DMSG
database that patients with a resected WHO G2 NF-pNET larger
than 2 cm had the highest risk of developing liver metastases.31
In the present study, WHO G2 or G3 tumors posed a 2.5 times
increased risk for LMFS compared to G1 tumors in pNETs of 2 cm
or larger. Although a number of patients with NF-pNETs was
included in the previous DMSG study,31 the present analysis
showed that WHO grade is associated with postoperative LMFS
also in patients with resected MEN1-related insulinomas, irre-
spective of age and size. In line, patients with a resectedWHO G2
of 2 cm had a reduced 10-year LMFS compared to those with G1
tumor of at least 2 cm (23% vs 65% for NF-pNETs and 57% vs 81%
for insulinomas, respectively). Considering the relatively low
number of outcomes, multivariable analysis was restricted to
age at surgery, size, functionality, and WHO grade. Nevertheless,
in univariable analysis, time from diagnosis until surgery was
associated with LMFS, specifically in patients with a resected
insulinoma. Despite that some CIs (barely) crossed unity, within
the subgroups of patients with a resected NF-pNET and insuli-
noma, higher age at surgery, larger tumors, a pNET of 2 cm or
larger, and WHO G2 or G3 increased the risk of liver metastasesTable V
Association between tumor size and LMFS
Size LMFS*
5-y (%) 10-y (%) Log rank P va
Overall
<2 cm 95 87 < .001
2e3 cm 98 93
3 cm 78 50
NF-pNET subgroup
<2 cm 86 86 .012
2e3 cm 100 86
3 cm 71 33
Insulinoma subgroup
<2 cm 100 86 .046
2e3 cm 97 97
3 cm 92 73
cat, category; Ref, reference.
* Estimated survival percentages are based on the p
y Data presented after multiple imputation.or death and could, therefore, be used for postoperative
counseling.
Mutations in the interacting domains of menin, which affect
transcriptional regulationeJunD and CHES1, have been reported to
be associated with the prognosis of patients with MEN1-related
pNETs but have not been validated successfully.12,16,42,43 More
recently, tumor-based transcription factors ARX and PDX1 have
been identified as enhancer signatures resembling a distinct alpha
(ARX positive) or beta cell (PDX1 positive) subtype differentiation
in MEN1-related pNETs. These subtypes subsequently affect prog-
nosis and imply differences in cell lineages of origin responsible for
the development of distinct subtypes of pNETs, which justify the
present clinical observations.44,45 Liver metastases were reported
almost exclusively in patients with ARX positive tumors, whereas
patients with PDX1 positive tumors had a generally low risk.44
Although these immunohistochemical markers were not studied
in the present study, one might reason that a higher proportion of
NF-pNETs will harbor a true alpha cell differentiation, whereas
insulinomas will generally resemble a beta cell differentiation. A
small subgroup of insulinomasewhich developed liver
metastasesepossibly harbors an alpha cell differentiation. This
should be investigated in future studies in MEN1-related pNETs
within a large and international cohort with surgical specimen
collection and adequate follow-up. In addition, unraveling these
differences in tumor biology might lead to subtype specific size
cutoffs for operative resection.
Apart from long-term outcomes, pathological characteristics
might reflect the more aggressive behavior of NF-pNETs because of
early spread to regional lymph nodes. Within the 73 patients with
lymph nodes removed, metastatic lymph nodes were more often
observed in NF-pNETs compared to insulinomas (56% vs 10%) and in
those with a pNET of 2 cm or larger (39% vs 16%). Patients with
lymph node metastases had an almost 3 times higher risk of liver
metastases or death than patients without lymph node metastases,
which is supported by 10-year LMFS probabilities of 51% in the
entire cohort and 44% in the subgroup of NF-pNETs. Although
lymph nodes were resected in only 73 patients, it is unlikely that
this has influenced the observations, since LMFS was similar be-
tween those with tumor negative lymph nodes and those without
lymphadenectomy. In at least 40% of patients, no lymph nodes were
resected, which might reflect the absence of guideline recom-
mendations regarding lymph node resections in MEN1.17,40 Euro-
pean Neuroendocrine Tumor Society guidelines recommend
routine dissection of lymph nodes in noninsulinoma pNETs.40
Current data might substantiate these recommendations also forUnivariable Cox regressiony
lue LM/death Crude HR 95% CI
9 of 62 1 Ref cat
7 of 50 1.46 0.50e4.27
21 of 41 4.80 2.09e11.02
5 of 21 1 Ref cat
3 of 13 1.36 0.29e6.28
14 of 27 3.21 1.14e9.06
3 of 40 1 Ref cat
4 of 37 1.95 0.44e8.68
8 of 15 5.47 1.45e20.63
atients with complete data.
Fig 5. LMFS according to pathology. n, number.
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positive lymph nodes compared to 18 patients with NF-pNETs.
Nevertheless, only 5 patients (3%)eall in the NF-pNET groupehad
suspected lymph node metastases on preoperative conventional
imaging. 68Ga labelled positron emission tomography (PET)/CT
might overcome the limitations of conventional imaging in this
matter.46,47 Nevertheless, the diagnostic, prognostic, and thera-
peutic implications of pNET-related lymph node metastases in
patients with MEN1 should be investigated in future studies.
The major strength of the present study is that it represents the
largest cohort of patients with resectedMEN1-related pNETs to date.
Histopathological data were available by including surgically treated
patients, which has provided the unique opportunity to adjust for
and study tumor size and grade. Patients were included over a recent
period whereMEN1 patients are screened and followed according to
guidelines.17 Missing data were retrieved as far as possible and
otherwise handled using multiple imputationegenerating a suffi-
cient number of datasetsewhich is currently considered as the best
available statistical method.35,48,49 In addition, several statistical
analyses, including Kaplan-Meier and Cox proportional hazard
regression, were conducted to derive statistically sound conclusions.
Despite the low prevalence of MEN1 and relatively low event rate,
even multivariable analyses were performed. Nevertheless, a larger
study population would enable more extensive multivariable ana-
lyses. Data frompatients undergoing surgery for NF-pNETs in centers
not included in the DMSG were not available, which is the main
limitation of the present study. Inclusion of those patients could have
led to a more homogeneous cohort. In addition, by including only
patients undergoing surgery, the question remains as to whether the
results are generalizable for patients not being exposed to operative
resection. Patients with other MEN1-related duodenopancreatic
neuroendocrine tumors (dpNETs), such as gastrinomas or rare
functioning pNETs were not included. Furthermore, determining the
origin of livermetastases is challenging considering themultifocalityof dpNETs in MEN1, eg, only 2 of the 6 patients with a resected
insulinoma had recurrent hypoglycemia at the time of liver metas-
tases. The exact number of resected andmetastatic lymph nodeswas
unknown, and therefore, patients were grouped into metastases, no
metastases, or no lymph nodes resected regardless of the number of
lymph nodes analyzed. Imaging (ie, presence of liver metastases)
and histopathological specimens (ie, WHO grade) were not centrally
collected and reassessed for the purpose of this study.
Pre and postoperative localization of insulinomas is challenging
in the presence of diffuse background adenomatosis in MEN1. In
the preoperative setting, ⁶⁸Ga-DOTA-Exendin-4 PET/CT can suc-
cessfully localize insulinomas in MEN1.50 Postoperatively, immu-
nohistochemistry is still the most widely available and used
method to identify the insulinoma. Most sporadically occurring
insulinomas express insulin.51 Nevertheless, in MEN1, multiple
pNETs might show immunoreactivity for insulin, and insulinomas
might be negative for insulin.51,52 Insulin negative insulinomas
were observed in 3, all of whom were biochemically cured, and
multiple insulin immunopositive pNETs were encountered in 24.
Insulinomas show positive immunohistochemistry signals specif-
ically for PDX1.44 Therefore, PDX1 might be additionally used or
replace insulin immunohistochemistry to overcome limitations
encountered in clinical practice.
The differences in prognosis after surgery for MEN1-related
pNETs is of direct clinical importance for postoperative patient
counseling and monitoring during follow-up, regarding in-
tensity and use of diagnostic modalities, to optimize care
in MEN1. Based on the present data, at least tumor functionality,
tumor size, and grade should be taken into account during
postoperative MEN1 care. Patients with resected
insulinomaseespecially if small and WHO G1ecan be counseled
about the low likelihood of metastases, and the aim of the
follow-up should be the detection and follow-up of new (NF)-
pNETs. The follow-up of MEN1-related NF-pNETs should focus
D.-J. van Beek et al. / Surgery xxx (2020) 1e1110on identifying metastatic disease. Regardless of functionality,
those withWHO G2 or G3 or large tumors have an increased risk.
In patients with an increased risk of liver metastases, 68Ga
labelled PET/CT might be used to identify metastatic disease to
enable timely initiation of adjuvant therapy. Furthermore,
regardless of tumor origin, patients should be counseled about
the risk of recurrence 5 or 10 years after surgery, which addi-
tionally underscores long-term follow-up of patients with
resected MEN1-related pNETs. Whether these observations will
alter the currently accepted 2 cm criterion should be investi-
gated in future studies. Additional studies should investigate the
optimal surgical strategy and determine the added value of
routine lymphadenectomy for the individual MEN1 patient,
taking long-term oncological outcomes, survival, future occur-
rence of clinically relevant dpNETs, and postoperative compli-
cations as well as pancreatic function and quality of life into
account.
In conclusion, patients with resected MEN1-related NF-pNETs
have a lower LMFS than those with insulinomas. These tumors
should therefore be regarded as distinct entities of MEN1-related
pNETs. Postoperative counseling and follow-up regimens should
be subtype specific and, additionally at least, be guided by size and
WHO grade.
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